This week, the San Diego-based bioprinting company Organovo announced their plan to develop 3D bioprinted human liver tissues for direct transplantation to patients. After successful string of preclinical studies in animal models, the new program will focus on acute-on-chronic liver failure (“ACLF”), which is a distinct disease that leads to an acute deterioration of liver function, as well as pediatric metabolic liver diseases. These 3D bioprinted liver tissue patches could soon help reduce the number of individuals stuck on a transplant list, or at the very least, extend their health for a few additional years before a full transplant is needed. Read more at 3DPrint.com: https://3dprint.com/151566/organov-3d-bioprinted-liver/